Tech Company Financing Transactions
Rege Nephro Funding Round
On 10/8/2024, Rege Nephro raised $17 million in Series B funding from Asahi Kasei, Global Brain and JAFCO.
Transaction Overview
Company Name
Announced On
10/8/2024
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series B
Investors
Proceeds Purpose
Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Med-Pharm Collaboration bldg. Kyoto University 46-29 Yoshida
Kyoto, 606-8501
Japan
Kyoto, 606-8501
Japan
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Research and develop various solutions for renal diseases, improve QOL of patients suffering from renal diseases, and contribute to society. The kidney is said to be an organ that cannot be repaired once it is broken, and there is still no essential cure except for kidney transplantation. Aside from research, the founder, Osafune, has been treating many kidney disease patients as a nephrologist, and has been concerned about the suffering and stress that patients have every day.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Akifumi Morinaka
Chief Financial Officer
Katsuhisa Yamaguchi
Founder
Kenji Osafune
VP - Manufacturing
Yoshifumi Kobayashi
VP - R & D
Tsuyoshi Nakano
Browse more venture capital transactions:
Prev: 10/7/2024: Chartbeat venture capital transaction
Next: 10/8/2024: Generare venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs